According to Zacks, “Although Teva is working on the integration of Actavis Generics and progressing with its branded pipeline, headwinds persist in the form of generic competition for Copaxone, as well as competition for branded products. Meanwhile, the generics segment could remain under pressure due to pricing erosion as well as the absence of important new product launches. However, the Actavis Generics acquisition will help Teva strengthen its position in key generic markets. Teva continues to progress with its branded and generics drugs pipeline and is looking to strengthen its biosimilar pipeline. Meanwhile, Teva intends to accelerate growth platforms, protect and expand core franchises, expand its global presence, pursue strategic deals and reduce the cost base. Estimates have been going down ahead of the company’s Q3 earnings release. The company has a positive record of earnings surprises in recent quarters.”
Several other equities research analysts also recently commented on TEVA. Mizuho reaffirmed a buy rating on shares of Teva Pharmaceutical Industries in a report on Sunday, July 17th. RBC Capital Markets set a $71.00 price objective on Teva Pharmaceutical Industries and gave the stock a buy rating in a research note on Sunday, September 11th. Maxim Group reissued a buy rating on shares of Teva Pharmaceutical Industries in a research note on Monday, July 18th. Credit Suisse Group AG reissued a neutral rating and issued a $51.63 price objective (down from $59.00) on shares of Teva Pharmaceutical Industries in a research note on Thursday, August 25th. Finally, Oppenheimer Holdings Inc. set a $66.00 price objective on Teva Pharmaceutical Industries and gave the stock a buy rating in a research note on Monday, September 12th. One research analyst has rated the stock with a sell rating, six have given a hold rating, twenty have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus target price of $66.94.
Teva Pharmaceutical Industries (NYSE:TEVA) opened at 42.96 on Wednesday. The firm has a 50-day moving average price of $48.87 and a 200-day moving average price of $52.17. The stock has a market cap of $39.27 billion, a PE ratio of 28.70 and a beta of 0.74. Teva Pharmaceutical Industries has a 12-month low of $42.95 and a 12-month high of $66.55.
Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Thursday, August 4th. The company reported $1.25 EPS for the quarter, beating the consensus estimate of $1.20 by $0.05. Teva Pharmaceutical Industries had a return on equity of 17.77% and a net margin of 7.56%. The business earned $5 billion during the quarter, compared to the consensus estimate of $4.86 billion. During the same period in the prior year, the business posted $1.43 earnings per share. Teva Pharmaceutical Industries’s revenue was up 1.4% compared to the same quarter last year. Analysts forecast that Teva Pharmaceutical Industries will post $5.24 EPS for the current fiscal year.
Institutional investors have recently modified their holdings of the stock. Advisor Consultant Network Inc. acquired a new position in shares of Teva Pharmaceutical Industries during the third quarter valued at about $7,842,000. Webster Bank N. A. increased its position in shares of Teva Pharmaceutical Industries by 6.1% in the third quarter. Webster Bank N. A. now owns 9,169 shares of the company’s stock valued at $422,000 after buying an additional 531 shares during the last quarter. Charter Trust Co. increased its position in shares of Teva Pharmaceutical Industries by 7.6% in the third quarter. Charter Trust Co. now owns 15,535 shares of the company’s stock valued at $714,000 after buying an additional 1,100 shares during the last quarter. Private Bank & Trust Co. increased its position in shares of Teva Pharmaceutical Industries by 7.5% in the third quarter. Private Bank & Trust Co. now owns 7,492 shares of the company’s stock valued at $345,000 after buying an additional 522 shares during the last quarter. Finally, AT Bancorp acquired a new position in shares of Teva Pharmaceutical Industries during the third quarter valued at about $861,000. Hedge funds and other institutional investors own 63.36% of the company’s stock.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teva Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.